INFUSENSE LLC

Nashville, TN · CIK 0001659412 · Medtech · Private

Biosensor platform for real-time drug concentration measurement

infusense.com →
Grants
$1.5M
2 awards
Sector median: 1
Raised
$2.0M
2 Form D · Jun 2025
15 months since last filing
Contracts
$150K
1 award · Defense
#484 of 4531 in medtech
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Defense · #12257014 Tatrc SBIR Phase H122-012-0163$149,984
Private capital raisedForm D · SEC$600,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Point-of-Care Electrochemical Platform for the Rapid Detection of Drug Toxicity$253,590
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Point-of-Care Electrochemical Platform for the Rapid Detection of Drug Toxicity$1,199,822
Private capital raisedForm D · SEC$1,390,000
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
481ENDECTRA LLC$150K—
482SPECTRAL MOLECULAR IMAGING, INC.$150K—
483MICROHORTONE LLC$150K—
484INFUSENSE LLC$150K$2.0M
485CELL PRESERVATION SERVICES INC$150K—
486Transient Electronics Inc.$150K—
487SOFTSONICS LLC$150K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Edward ChaumDirector · Executive Officer
  • EDWARD CHAUMDirector
  • Eric KriegsteinExecutive Officer
  • BRUCE LANDAUDirector
  • ANDY SASLAWSKYDirector

Patents

USPTO · 1 granted of 3

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.